Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

In Vivo Delivery of a CD20 CAR Using a CD8-Targeted Fusosome in Southern Pig-Tail Macaques ( M. nemestrina ) Results in B Cell Depletion

Blood (2021) 138 (Supplement 1): 2769.

https://doi.org/10.1182/blood-2021-148709

Published: 2021

Journal Articles

CD4-Targeted Fusosomes Are Capable of Transducing Resting T Helper Cells to Generate Highly Potent CAR-T Cells

Christie Ciarlo, Zach Frye, Andre DeGroot, Walter Flores, Kutlu Elpek, Lauren Pepper, Adam Johnson, Jagesh V Shah, Aaron E. Foster, Terry J. Fry

Blood (2021) 138 (Supplement 1): 2942.

https://doi.org/10.1182/blood-2021-148469

Published: 2021

Journal Articles

Engineered Hypoimmune Allogeneic CAR T Cells Exhibit Innate and Adaptive Immune Evasion Even after Sensitization in Humanized Mice and Retain Potent Anti-Tumor Activity

Xiaomeng Hu, Mo Dao, Kathy White, Corie Gattis, Ryan Clarke, Sam Landry, Ron Basco, Eleonore Tham, Andrew Tucker, Emily Luo, Christopher Bandoro, Elaine Chu, Chi Young, Aaron E. Foster, William E Dowdle, Edward J Rebar, Terry J. Fry, Sonja Schrepfer

Blood (2021) 138 (Supplement 1): 1690.

https://doi.org/10.1182/blood-2021-150021

Published: 2021

Journal Articles

Preclinical Development of Inducible MyD88/CD40 (iMC)-Enhanced Chimeric Antigen Receptor Natural Killer (GoCAR-NK) Cells to Target BCMA + Tumors

Xiaomei Wang, PhD, MyLinh T Duong, PhD, Alan D. Guerrero, PhD, Aruna Mahendravada, MS, Kelly L Sharp, BS, Mary E. Brandt, BS, Christine Gagliardi, PhD, Aaron E. Foster, PhD, J. Henri Bayle, PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140848

Published: 2020

Journal Articles

Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in Myeloma

Tsvetelina Pentcheva-Hoang, PhD, David Torres, Tania Rodriguez, PhD, Ana Korngold, PhD, An Lu, Jeannette Crisostomo, Annemarie Moseley, MD PhD, Lorenz Jahn, Mirjam H.M. Heemskerk, PhD, Kevin M Slawin, MD, David M Spencer, PhD, Aaron E Foster, PhD

Blood (2016) 128 (22): 4550.

https://doi.org/10.1182/blood.V128.22.4550.4550

Published: 2016

Journal Articles

Inducible MyD88/CD40 (iMC) Costimulation Provides Ligand-Dependent Tumor Eradication By CD123-Specific Chimeric Antigen Receptor T Cells

Aaron E Foster, PhD, MyLinh Duong, PhD, An Lu, Peter Chang, PhD, Aruna Mahendravada, Nicholas Shinners, PhD, Kevin M Slawin, MD, J. Henri Bayle, PhD, David M Spencer, PhD

Blood (2016) 128 (22): 4551.

https://doi.org/10.1182/blood.V128.22.4551.4551

Published: 2016

Journal Articles

Vaccination with ΔCD40L or Flagellin Gene-Modified T Cells Activates Dendritic Cells In Vivo and Induces a Potent Anti-Tumor Immune Response

Adham S Bear, Meghan M Turnis, PhD, Xiao-Tong Song, PhD, Russell Cruz, MD, An Lu, Stephen Gottschalk, MD, Cliona M Rooney, PhD, Aaron E Foster, PhD

Blood (2011) 118 (21): 1909.

https://doi.org/10.1182/blood.V118.21.1909.1909

Published: 2011

Journal Articles

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

Antonio Di Stasi, Biagio De Angelis, Cliona M. Rooney, Lan Zhang, Aruna Mahendravada, Aaron E. Foster, Helen E. Heslop, Malcolm K. Brenner, Gianpietro Dotti, Barbara Savoldo

Blood (2009) 113 (25): 6392–6402.

https://doi.org/10.1182/blood-2009-03-209650

Published: 2009

Journal Articles

Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9

Juan F Vera, MD, Valentina Hoyos, MD, Barbara Savoldo, MD, Concetta Quintarelli, PhD, Greta A Giordano, Ann M. Leen, PhD, Hao Liu, Aaron E. Foster, PhD, Helen E. Heslop, MD, Cliona M Rooney, PhD, Malcolm K Brenner, MD, PhD, Gianpietro Dotti, MD

Blood (2008) 112 (11): 3534.

https://doi.org/10.1182/blood.V112.11.3534.3534

Published: 2008

Journal Articles

Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes

Concetta Quintarelli, Juan F. Vera, Barbara Savoldo, Greta M. P. Giordano Attianese, Martin Pule, Aaron E. Foster, Helen E. Heslop, Cliona M. Rooney, Malcolm K. Brenner, Gianpietro Dotti

Blood (2007) 110 (8): 2793–2802.

https://doi.org/10.1182/blood-2007-02-072843

Published: 2007

Includes: Supplemental data

Journal Articles

Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease

Barbara Savoldo, Cliona M. Rooney, Antonio Di Stasi, Hinrich Abken, Andreas Hombach, Aaron E. Foster, Lan Zhang, Helen E. Heslop, Malcolm K. Brenner, Gianpietro Dotti

Blood (2007) 110 (7): 2620–2630.

https://doi.org/10.1182/blood-2006-11-059139

Published: 2007

Includes: Supplemental data

Journal Articles

Immune Responses Are Induced Against Side-Population B-CLL “Stem Cells ” by Patient Vaccination with hCD40L/IL2 Gene Modified Tumor Cells.

Aaron E. Foster, PhD, Gianpietro Dotti, MD, An Lu, Michael Andreeff, MD, Margaret Goodell, PhD, Cliona M. Rooney, PhD, Malcolm K. Brenner, MD

Blood (2006) 108 (11): 2552.

https://doi.org/10.1182/blood.V108.11.2552.2552

Published: 2006

Journal Articles

IL-21 Gene Modified T Antigen Presenting Cells Enhance the Generation of Tumor-Specific Cytotoxic T Lymphocytes with a Memory Phenotype.

Anjum S. Kaka, MD, Ryan Hartmeier, Ann M. Leen, PhD, An Lu, Cliona M. Rooney, PhD, Aaron E. Foster, PhD

Blood (2006) 108 (11): 3709.

https://doi.org/10.1182/blood.V108.11.3709.3709

Published: 2006

Journal Articles

Ex-Vivo Expansion and Prophylactic Infusion of CMV pp65 Specific CTL Following Haemopoietic Stem Cell Transplantation (HSCT).

David J. Gottlieb, MD, FRACP, Anna M. Hansen, PhD, Ken P. Micklethwaite, MB, Aaron E. Foster, PhD, Cameron J. Turtle, MB PhD FRACP, Vicki Antonenas, MSc, Mary M. Sartor, MSc, Ken F. Bradstock, MB PhD FRACP

Blood (2005) 106 (11): 3244.

https://doi.org/10.1182/blood.V106.11.3244.3244

Published: 2005

Journal Articles

Human CD62L – memory T cells are less responsive to alloantigen stimulation than CD62L + naive T cells: potential for adoptive immunotherapy and allodepletion

Aaron E. Foster, Marina Marangolo, Mary M. Sartor, Stephen I. Alexander, Min Hu, Kenneth F. Bradstock, David J. Gottlieb

Blood (2004) 104 (8): 2403–2409.

https://doi.org/10.1182/blood-2003-12-4431

Published: 2004

NARROW

In Vivo Delivery of a CD20 CAR Using a CD8-Targeted Fusosome in Southern Pig-Tail Macaques ( M. nemestrina ) Results in B Cell Depletion

CD4-Targeted Fusosomes Are Capable of Transducing Resting T Helper Cells to Generate Highly Potent CAR-T Cells

Engineered Hypoimmune Allogeneic CAR T Cells Exhibit Innate and Adaptive Immune Evasion Even after Sensitization in Humanized Mice and Retain Potent Anti-Tumor Activity

Preclinical Development of Inducible MyD88/CD40 (iMC)-Enhanced Chimeric Antigen Receptor Natural Killer (GoCAR-NK) Cells to Target BCMA + Tumors

Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in Myeloma

Inducible MyD88/CD40 (iMC) Costimulation Provides Ligand-Dependent Tumor Eradication By CD123-Specific Chimeric Antigen Receptor T Cells

Vaccination with ΔCD40L or Flagellin Gene-Modified T Cells Activates Dendritic Cells In Vivo and Induces a Potent Anti-Tumor Immune Response

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9

Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes

Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease

Immune Responses Are Induced Against Side-Population B-CLL “Stem Cells ” by Patient Vaccination with hCD40L/IL2 Gene Modified Tumor Cells.

IL-21 Gene Modified T Antigen Presenting Cells Enhance the Generation of Tumor-Specific Cytotoxic T Lymphocytes with a Memory Phenotype.

Ex-Vivo Expansion and Prophylactic Infusion of CMV pp65 Specific CTL Following Haemopoietic Stem Cell Transplantation (HSCT).

Human CD62L – memory T cells are less responsive to alloantigen stimulation than CD62L + naive T cells: potential for adoptive immunotherapy and allodepletion

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only